Gram Research analysis shows that vitamin D (calcitriol) reduces psoriasis by shutting down a protein called CHI3L2 through a cellular pathway called STAT3. In laboratory studies using mice and human skin cells, vitamin D decreased skin inflammation, stopped excessive skin cell growth, and lowered inflammatory chemicals that drive psoriasis. While this mechanism is now understood, human clinical trials are still needed to confirm these benefits in patients.
Researchers discovered how vitamin D (specifically calcitriol, its active form) fights psoriasis by turning off a problematic protein called CHI3L2. In laboratory and mouse studies, calcitriol reduced skin inflammation, stopped excessive skin cell growth, and lowered inflammatory chemicals that make psoriasis worse. The study identified a specific pathway in cells that controls this protein, suggesting CHI3L2 could become a new target for psoriasis treatments. This research helps explain why vitamin D has long been used to treat psoriasis and opens doors for developing better therapies.
Key Statistics
A 2026 laboratory study published in the Journal of Cellular and Molecular Medicine found that vitamin D (calcitriol) reduced pro-inflammatory cytokine expression including IL-6, IL-17A, and IL-23A in mouse models of psoriasis-like skin lesions.
Researchers identified CHI3L2 as the most significantly downregulated gene following calcitriol treatment in human skin cells, suggesting it is the primary molecular target through which vitamin D exerts its anti-psoriatic effects.
When CHI3L2 protein was directly reduced in laboratory skin cells without adding vitamin D, cells showed the same protective benefits including suppressed proliferation, reduced migration, and decreased inflammatory responses as cells treated with vitamin D alone.
The Quick Take
- What they studied: How vitamin D (calcitriol) reduces psoriasis symptoms and what protein it targets to do this
- Who participated: Laboratory experiments using mouse skin models and human skin cells grown in dishes, not human patients
- Key finding: Vitamin D works by shutting down a protein called CHI3L2, which reduces skin inflammation and stops skin cells from multiplying too fast
- What it means for you: This research is early-stage laboratory work that may eventually lead to new psoriasis treatments, but it does not yet mean vitamin D supplements will cure psoriasis in people. Talk to your doctor before using vitamin D for psoriasis treatment.
The Research Details
Scientists conducted laboratory experiments using two approaches. First, they applied vitamin D to mouse ears that had been treated with a chemical to create psoriasis-like skin lesions. They measured how much the skin improved by looking at inflammation markers and skin thickness. Second, they grew human skin cells in dishes and treated them with vitamin D to see what changed at the molecular level. They used advanced genetic testing (RNA-seq) to identify which genes turned on or off when vitamin D was applied. Finally, they tested whether directly reducing the CHI3L2 protein produced the same protective effects as vitamin D treatment.
This multi-layered approach allowed researchers to move from observing benefits in living tissue to understanding the exact molecular mechanism. By testing whether removing CHI3L2 alone could replicate vitamin D’s effects, they established that this protein is the key player in vitamin D’s anti-psoriasis action.
The study design is strong for laboratory research because it combines in-vivo models (living organisms) with in-vitro models (cells in dishes) and uses modern genetic analysis to identify the specific pathway involved.
Understanding the exact mechanism of how vitamin D works against psoriasis is crucial for developing better treatments. Rather than just knowing vitamin D helps, scientists now know which protein to target and which cellular pathway to influence. This knowledge allows pharmaceutical companies to design drugs that specifically block CHI3L2 or interfere with the STAT3 pathway, potentially creating more effective treatments with fewer side effects than current options.
This is laboratory research published in a peer-reviewed journal, which means other experts reviewed it before publication. However, the study was conducted in mice and cultured cells, not in human patients. Laboratory findings often do not translate directly to human treatments. The researchers used standard scientific methods and modern genetic analysis tools, which strengthens the reliability of their molecular findings. The study’s main limitation is that it has not yet been tested in human patients with psoriasis.
What the Results Show
When researchers applied vitamin D to mouse ears with psoriasis-like lesions, the skin improved significantly. Clinical scores (measurements of how severe the skin looked) decreased, the thickened skin returned closer to normal thickness, and levels of inflammatory chemicals (IL-1 alpha, IL-6, IL-17A, and IL-23A) dropped substantially. These are the same inflammatory chemicals that drive psoriasis in humans.
In human skin cells grown in the laboratory, vitamin D stopped cells from multiplying excessively, reduced their ability to migrate (move around), and lowered inflammatory responses. The cells also restored normal keratin expression, which is important for healthy skin barrier function.
The most important finding was that vitamin D works by reducing CHI3L2 protein levels. When researchers directly reduced CHI3L2 without adding vitamin D, the cells showed the same protective benefits, proving that CHI3L2 is the key target. The mechanism involves blocking STAT3 phosphorylation, a molecular switch that normally keeps CHI3L2 active.
The study identified CHI3L2 as the most significantly downregulated gene (turned off) when cells were treated with vitamin D, suggesting it is the primary target among thousands of genes. The restoration of keratin proteins (KRT1 and KRT6) indicates that vitamin D helps skin cells return to their normal, healthy state. The fact that both unilateral (one-sided) and bilateral (both-sided) mouse ear models showed improvement suggests the effect is consistent and reproducible.
Vitamin D has been used to treat psoriasis for decades, but doctors did not fully understand why it worked. This research provides the missing explanation by identifying CHI3L2 and the STAT3 pathway as the mechanism. Previous research showed that STAT3 is overactive in psoriasis, and this study confirms that vitamin D can suppress this overactivity. The findings align with existing knowledge that chitinase-like proteins are involved in inflammation, but this is the first study to specifically link CHI3L2 to psoriasis.
This study was conducted entirely in laboratory settings using mice and cultured cells, not in human patients with psoriasis. Results in mice do not always translate to humans due to differences in immune systems and skin biology. The study used topical (applied to skin) vitamin D in mice, but did not test oral supplements or injections. The research does not address whether this mechanism works in all types of psoriasis or in people with different genetic backgrounds. Long-term effects and potential side effects in humans remain unknown. The study also did not compare vitamin D to current psoriasis treatments to determine if it would be more effective.
The Bottom Line
This research is too early-stage to recommend vitamin D supplements specifically for psoriasis treatment based on this study alone. However, existing clinical evidence supports vitamin D’s role in psoriasis management. People with psoriasis should consult their dermatologist about whether vitamin D supplementation or topical vitamin D products are appropriate for their specific situation. This research suggests future drug development targeting CHI3L2 or STAT3 may offer new treatment options, but such drugs do not yet exist.
People with psoriasis and their doctors should follow this research as it develops toward human trials. Pharmaceutical researchers and dermatologists should consider CHI3L2 as a potential drug target. People without psoriasis do not need to change their vitamin D intake based on this study. This research is not relevant for other skin conditions unless they also involve CHI3L2 and STAT3 dysregulation.
Laboratory research typically takes 5 to 10 years to translate into human treatments. If this research leads to drug development, clinical trials in humans would need to occur before any new treatment becomes available. Existing vitamin D treatments for psoriasis may provide benefits within weeks to months, but individual responses vary.
Frequently Asked Questions
How does vitamin D help treat psoriasis?
Vitamin D (calcitriol) reduces psoriasis by turning off a protein called CHI3L2 through a cellular pathway called STAT3. This stops skin cells from multiplying too fast and reduces inflammatory chemicals that cause psoriasis symptoms like redness and thickening.
Can I take vitamin D supplements to cure my psoriasis?
This research is laboratory-based and has not yet been tested in human patients. While vitamin D has been used for psoriasis treatment, you should consult your dermatologist about whether supplements are appropriate for your specific situation and what dose is safe.
What is CHI3L2 and why does it matter for psoriasis?
CHI3L2 is a protein that promotes inflammation and tissue changes in skin. This study shows it is overactive in psoriasis and that vitamin D works by reducing CHI3L2 levels. Understanding this makes CHI3L2 a potential target for developing new psoriasis drugs.
When will new psoriasis treatments based on this research be available?
Laboratory discoveries typically take 5 to 10 years to become available treatments. Researchers would need to develop drugs targeting CHI3L2 or STAT3, then conduct human clinical trials before any new treatment could be approved and prescribed.
Does this research apply to all types of psoriasis?
This study was conducted in laboratory models and has not yet been tested in human patients with different types of psoriasis. Results may vary depending on individual genetics, psoriasis severity, and other factors. More research is needed to determine how broadly these findings apply.
Want to Apply This Research?
- Track daily vitamin D intake (in international units or IU) and weekly skin severity scores using a standardized scale (such as rating affected skin area as a percentage of body surface). Note any changes in redness, thickness, or itching of affected areas.
- If your doctor recommends vitamin D for psoriasis management, use the app to set reminders for consistent daily supplementation or topical application. Log which vitamin D product you use and note any skin improvements or side effects to discuss with your healthcare provider.
- Maintain a long-term log of vitamin D supplementation alongside monthly photos of affected skin areas and symptom severity ratings. Share this data with your dermatologist at regular appointments to assess whether vitamin D is helping your specific psoriasis.
This research is laboratory-based and has not been tested in human patients with psoriasis. The findings do not constitute medical advice or a recommendation to use vitamin D supplements for psoriasis treatment. Psoriasis is a complex condition that varies greatly between individuals. Anyone with psoriasis should consult with a dermatologist or healthcare provider before starting vitamin D supplementation or changing their treatment plan. Do not stop or replace current psoriasis medications based on this research. While vitamin D has been used historically for psoriasis management, the specific benefits and appropriate dosing should be determined by a qualified healthcare professional based on your individual medical history and current treatment regimen.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.